COMMUNIQUÉS West-GlobeNewswire

Healis selected to present at key biotechnology and neuroscience investor conferences in Amsterdam, New York, and San Diego
12/02/2024
NEWPORT BEACH, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce it has been competitively selected to present at several key investor conferences. At BIO-Neuroscience, held in [...]
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
12/02/2024
Projected Cash Runway Extends into Second Calendar Quarter 2026, Well Beyond Potential 1H 2025 Submission of GTX-104 New Drug Application (NDA) Patient Enrollment in Pivotal STRIVE-ON Phase 3 Trial Continues, On Track [...]
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
12/02/2024
Gastric cancer, ovarian cancer, myxoid/round cell liposarcoma and synovial sarcoma selected as initial clinical indications for lead program MDG1015 MDG1015 is a first-in-class, third generation TCR-T therapy targeting [...]
Smith+Nephew unveils expanded Sports Medicine portfolio to enable biological healing at AAOS 2024 Annual Meeting
12/02/2024
12 February 2024 Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the premiere of its newly acquired CARTIHEAL ◊ AGILI-C ◊ Cartilage Repair Implant alongside the REGENETEN ◊ Bioinductive [...]
Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD
12/02/2024
Bedtime TNX-102 SL improves sleep quality in PTSD and is also being developed for the management of fibromyalgia for which NDA preparation is ongoing Investigator-Initiated OASIS Trial at UNC is a Phase 2 180-patient, [...]
Spectral AI Appoints Dr. J. Michael DiMaio to Board of Directors
12/02/2024
The Company’s two largest stockholders holding approximately 45% of the Company’s outstanding shares have extended their lock-up agreements for an additional 180 days DALLAS, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Spectral [...]
Invizyne Technologies Announces Filing of Registration Statement for Proposed Offering and Listing on Nasdaq
12/02/2024
Monrovia, CA, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc. , a leading designer of enzyme-based biomanufacturing systems – and a subsidiary of MDB Capital Holdings, LLC , (NASDAQ:MDBH) ("MDB") – today [...]
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
12/02/2024
Approval triggered by positive results from ReSTORE Phase III clinical trial Payment will advance Cidara’s Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb. 12, 2024 (GLOBE NEWSWIRE [...]
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
12/02/2024
REDWOOD CITY, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular [...]
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
12/02/2024
4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO 2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all [...]
IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
12/02/2024
MONTREAL, Feb. 12, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 [...]
TECHNOLOGIES IBEX SIGNE UNE ENTENTE DÉFINITIVE VISANT LA VENTE DE LA SOCIÉTÉ POUR UNE CONTREPARTIE AU COMPTANT DE 1,45 $ PAR ACTION
12/02/2024
MONTRÉAL, 12 févr. 2024 (GLOBE NEWSWIRE) -- Technologies IBEX inc. (« IBEX » ou la « Société ») (Bourse de croissance TSX : IBT) est heureuse d’annoncer qu’elle a conclu une entente d’acquisition contraignante datée du [...]
VitalHub Announces First Canadian Licensing Agreement of the Award-Winning Intouch with Health Queue Management & Patient Journey Optimization Platform with Newfoundland & Labrador Health Services
12/02/2024
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX:VHI) (OTCQX:VHIBF) is pleased to announce the first Canadian customer for the Intouch with Health Queue Management & [...]
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
12/02/2024
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
12/02/2024
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BXCL701 is an [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12/02/2024
Bagsværd, Denmark, 12 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12/02/2024
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb. 12 [...]
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
12/02/2024
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26 [...]
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
12/02/2024
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it is now [...]

Pages